Dr. Ok is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcolmb Blvd
Unit 0072
Houston, TX 77030Phone+1 713-792-7030
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Hematopathology, 2012 - 2013
UMass Chan Medical SchoolResidency, Pathology-Anatomic and Clinical, 2008 - 2012
Yonsei University College of MedicineClass of 2004
Certifications & Licensure
TX State Medical License 2015 - 2025
MA State Medical License 2012 - 2017- American Board of Pathology Pathology - Anatomic/Pathology - Clinical
- American Board of Pathology Clinical Informatics
- American Board of Pathology Pathology - Molecular Genetic
- American Board of Pathology Hematopathology
Publications & Presentations
PubMed
- 2 citationsMantle cell lymphoma involving tonsils: a clinicopathologic study of 83 cases.Mehrnoosh Tashakori, Do Hwan Kim, Rashmi Kanagal-Shamanna, Francisco Vega, Roberto N. Miranda
Human Pathology. 2021-10-13 - 48 citationsPersistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia.Chi Young Ok, Sanam Loghavi, Dawen Sui, Peng Wei, Rashmi Kanagal-Shamanna
Haematologica. 2019-02-01 - 95 citationsTP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseasesChi Young Ok, Keyur P. Patel, Guillermo Garcia-Manero, Mark J. Routbort, Jie Peng
Journal of Hematology & Oncology. 2015-05-08
Journal Articles
- High-Grade B-cell Lymphomas with TdT Expression: A Diagnostic and Classification DilemmaChi Young Ok, L Jeffrey Medeiros, Sergej Konoplev, Nitin Jain, Elias Jabbour, Guilin Tang, Nature
Abstracts/Posters
- Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C...Chi Young Ok, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma _ Cohort Study of 369 PatientsChi Young Ok, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C...Chi Young Ok, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib E...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Clinical, Immunophenotypic and Genomic Findings  of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow P...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
